Voyager Therapeutics Inc. (Nasdaq: VYGR) entered an exclusive strategic collaboration and option agreement with AbbVie Inc. (NYSE: ABBV) to develop and commercialize vectorized antibodies to treat Alzheimer's disease. Shares of Voyager Therapeutics leaped $4.30 to close at $23.66 while AbbVie stock slipped 62 cents to close at $117.98.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.